BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 5, 2018
View Archived Issues
Early safety and efficacy data support use of MAGE-A4 SPEAR T cells for treatment of solid tumors
Read More
Targeting LILRB4 may augment immunotherapy in leukemia
Read More
First mouse model of Costello syndrome highlights role of altered metabolism in disease
Read More
A 20p11.2 deletion including FOXA2 causes hyperinsulinemic hypoglycemia
Read More
ZMYM2 -- a new candidate gene for congenital anomalies of the kidney and urinary tract
Read More
Acute kidney injury prevented in mice by prophylactic treatment with DNase I inhibitor
Read More
Obesity drives NASH, liver cancer via distinct mechanisms
Read More
Durable tumor responses reported for ODM-203 in phase I/II KIDES trial
Read More
Drugging "undruggable" zinc fingers
Read More
Clean antagonist antibody can control skin inflammation
Read More
BAY-1161909 in combination with paclitaxel demonstrates antitumor efficacy but trial terminated
Read More
Preliminary phase I results of ABBV-181 reported at ESMO
Read More
Limited antitumor efficacy and high rates of hypertension in breast cancer with lucitanib
Read More
AbbVie patents new BRD4 inhibitors
Read More
Zion Medical reports first clinical data for HIV drug Gammora
Read More
FDA approves pegfilgrastim biosimilar Udenyca
Read More
Cancer Research Technology identifies RET inhibitors
Read More
Phase III study of Venclexta with Gazyva in treatment-naive CLL meets primary endpoint
Read More
European Commission approves Symkevi in cystic fibrosis
Read More
FDA approves adalimumab biosimilar Hyrimoz
Read More
Interim phase I results reported for ISC-hpNSC cell therapy in Parkinson's disease patients
Read More
FDA issues complete response letter for oliceridine NDA
Read More
SanBio's phase II trial of SB-623 in traumatic brain injury meets primary endpoint
Read More
FDA approves Lorbrena for previously treated ALK-positive metastatic NSCLC
Read More
Leo Pharma opens phase Ib study of LEO-134310 in chronic plaque psoriasis
Read More
FDA approves Dsuvia for acute pain in healthcare settings
Read More
Recombinant Lassa-rabies virus vaccine LASSARAB protects guinea pigs from Lassa fever
Read More